Author(s): Wong KK, Engelman JA, Cantley LC
Abstract Share this page
Abstract The phosphoinositide 3-kinase (PI3K) pathway is activated in a variety of different human cancers, and inhibitors of this pathway are under active development as anti-cancer therapeutics. In this review, we discuss the data supporting the use of PI3K pathway inhibitors in genetically and clinically defined cancers. This review focuses on their efficacy as single agents and in combination with other targeted therapies, specifically those targeting the MEK-ERK signaling pathway. Copyright 2009 Elsevier Ltd. All rights reserved.
This article was published in Curr Opin Genet Dev
and referenced in Journal of Biodiversity, Bioprospecting and Development